花园生物(300401) - 2024 Q3 - 季度业绩预告

Performance Forecast Overview This section outlines the company's performance forecast for the first three quarters and Q3 2024, detailing expected growth in net profit Current Period Performance Forecast Zhejiang Huayuan Bio-pharmaceutical Co., Ltd. anticipates significant year-over-year growth in net profit attributable to shareholders and non-recurring net profit for both the first three quarters and Q3 2024 - The performance forecast period is from January 1 to September 30, 2024, with expected year-over-year growth[2] 2024 First Three Quarters Performance Forecast The company projects substantial year-over-year increases in net profit and non-recurring net profit for the first three quarters of 2024 2024 First Three Quarters Performance Forecast | Item | 2024 First Three Quarters Forecast (CNY 10,000) | Year-over-Year Growth (%) | 2023 First Three Quarters (CNY 10,000) | | :---------------------------------------------- | :-------------------------------------- | :------------------------ | :----------------------------------- | | Net Profit Attributable to Shareholders | 23,200 – 26,200 | 55.77 – 75.92 | 14,893.33 | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 19,200 – 22,200 | 44.39 – 66.96 | 13,296.88 | 2024 Third Quarter Performance Forecast The company anticipates significant year-over-year growth in net profit and non-recurring net profit for the third quarter of 2024 2024 Third Quarter Performance Forecast | Item | 2024 Third Quarter Forecast (CNY 10,000) | Year-over-Year Growth (%) | 2023 Third Quarter (CNY 10,000) | | :---------------------------------------------- | :------------------------------------- | :------------------------ | :------------------------------ | | Net Profit Attributable to Shareholders | 9,000 – 12,000 | 183.68 – 278.25 | 3,172.54 | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 8,300 – 11,300 | 203.38 – 313.03 | 2,735.85 | Communication with Accounting Firms The financial data in this performance forecast is a preliminary estimate by the company's finance department and has not been audited by certified public accountants - The financial data related to this performance forecast has not been audited by certified public accountants[3] Explanation of Performance Changes The company's performance growth is primarily driven by increased revenue and gross profit in the vitamin segment, reduced share-based payment expenses, and positive impact from non-recurring gains (asset disposal income) - During the reporting period, the vitamin segment's operating revenue and gross profit increased year-over-year, serving as a key driver for performance growth[3] - The expiration of the first and additional lock-up periods for the company's 2022 employee stock ownership plan led to a year-over-year decrease in recognized share-based payment expenses for the current period[3] - Non-recurring gains are expected to contribute approximately CNY 40 million in net profit, primarily from asset disposal income recognized after a subsidiary completed its relocation[3] Risk Warning The company advises investors that this performance forecast is a preliminary estimate, and final financial data will be based on the 2024 Third Quarter Report, urging cautious investment decisions - This performance forecast represents preliminary estimates by the company's finance department, not final audited data[3] - Detailed financial data will be fully disclosed in the 2024 Third Quarter Report[3] - Investors are advised to make cautious decisions and be aware of investment risks[3]